CA
NZ
UK
AU
IND
US
ProKidney Corp. (NASDAQ: PROK) reported a net loss of $46.4 million for the second quarter ended June 30, starkly highlighting financial challenges as the company navigates ongoing projects. Cash and equivalents, important for operations, decreased to $181.6 million from $224.9 million at the end …
RADNET, INC. (NASDAQ: RDNT) reported second-quarter revenue of $622.7 million, marking a significant 25% increase from $498.2 million in the same period last year. This substantial growth outpaced analysts' expectations, as the company had previously recorded aDiluted Earnings per Shareof $-0.28 in the first …
The trial achieved a response rate of 88%, far exceeding the 19% observed in the placebo group. This remarkable performance is important as it indicates divesiran's promising potential in a space with few adequate treatment options, making it a compelling story for healthcare investors.
Trulieve Cannabis Corp reported significant progress in its second-quarter earnings, achieving $271 million in revenue, driven largely by medical-only sales that climbed 4% from the previous quarter to $222 million. This continuedDemandfor medical cannabis underscores the company’s strong operational performance. Despite a net loss …
Leadership Changes Within Viromed Medical AG
Perspective Therapeutics, Inc. (NYSE American: CATX) reported a net loss of $26.8 million for the quarter that ended June 30, 2026. This represents an increase from the $21.5 million loss recorded a year earlier. The company's performance was also compared to earlier estimates, as …
Quanterix Corporation's (NASDAQ: QTRX) revenue for the second quarter reached $32.9 million, marking a 34% increase from $24.5 million in Q2 of the previous year. However, this figure fell short of analysts' expectations, who had projected a loss per share of $-0.47, with the …
Rocket Pharmaceuticals, Inc. reported a strong net income of $123.2 million for the second quarter ending June 30, 2026, bouncing back from a net loss of $68.9 million recorded in the same quarter last year. The substantial turnaround positions Rocket not only as a …
With this positive earnings surprise, P3 has capitalized on its operational restructuring, resulting in revenue growth of 9% to $386 million. Shares rose 26.8% to $16.27 in after-hours trading, reflecting market optimism about the company’s future performance.
QuidelOrtho Corporation (NASDAQ: QDEL) recorded a strong $631 million in total revenue for the second quarter of 2026, marking a 3% increase from the previous year. The revenue growth was largely driven by the Labs segment, which generated $383 million and increased by 4%. …
Please wait processing your request...